This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ASCO 2018

Find information on Boehringer Ingelheim's clinical data and activities at ASCO 2018.

This event has ended

We are dedicated to collaborating with the oncology community on a shared journey to deliver leading science.

To that end, Boehringer Ingelheim is supporting the ASCO Conquer Cancer Young Investigator Award, which brings our long—term partnership with ASCO to yet another level to support cancer research.

Please see below for the downloadable versions of the presentations from the congress related to our activities.

Presentations

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: June 2018